Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric-based diseases and disorders in the United States. The company offers INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia; ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of endometriosis pain; and ORIAHNN, a GnRH antagonist for the management of heavy menstrual bleeding associated with uterine fibroids. Its product candidates in clinical development include valbenazine, which is in Phase III clinical trial for the treatment of chorea in Huntington's disease; NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of pediatric patients, as well as other indications, such as adult focal epilepsy; NBI-827104, an orally active and brain penetrating T-type calcium channel blocker for treating rare pediatric epilepsy and other indications; and NBI-74788, which is in Phase III clinical trial for the treatment of congenital adrenal hyperplasia. The company's products under development include NBI-1065844, a D-amino acid oxidase inhibitor for the treatment of negative symptoms of schizophrenia; NBI-1065845, an alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid potentiator for the treatment of resistant depression; and NBI-1065846, a G protein-coupled receptor 139 agonist for treating anhedonia in depression. It has collaborations and agreements with Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Â Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; AbbVie Inc.; and Sentia Medical Sciences Inc. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
IPO Year: 1996
Exchange: NASDAQ
Website: neurocrine.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/11/2025 | $138.00 | Hold | Deutsche Bank |
| 10/10/2024 | $155.00 | Outperform | Raymond James |
| 8/29/2024 | $131.00 → $159.00 | Neutral → Overweight | Piper Sandler |
| 4/24/2024 | $140.00 → $170.00 | Equal Weight → Overweight | Wells Fargo |
| 12/13/2023 | $127.00 | Neutral | Citigroup |
| 12/12/2023 | $136.00 | Buy | Deutsche Bank |
| 10/24/2023 | $135.00 → $140.00 | Overweight | Cantor Fitzgerald |
| 8/21/2023 | $112.00 → $113.00 | Neutral | Mizuho |
| 7/24/2023 | $115.00 → $125.00 | Market Perform → Outperform | SVB Securities |
| 7/6/2023 | $91.00 → $96.00 | Underperform → Market Perform | BMO Capital Markets |
For Immediate Release: December 13, 2024 Today, the U.S. Food and Drug Administration approved Crenessity (crinecerfont) to be used together with glucocorticoids (steroids) to control androgen (a testosterone-like hormone) levels in adults and pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH).“Today’s approval provides an important advance for patients with classic con
4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
SAN DIEGO, Feb. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that its Board of Directors has authorized a new share repurchase program under which Neurocrine Biosciences may repurchase up to $500 million of its shares, subject to market conditions. This new share repurchase authorization is in addition to the $300 million accelerated repurchase program that was announced in October 2024 and completed in early February 2025. William Rastetter, Chairman of the Board of Directors of Neurocrine Biosciences, said, "This authorization reflects
INGREZZA® (valbenazine) Fourth Quarter and Full Year 2024 Net Product Sales of $615 Million and $2.3 Billion, Representing Year-Over-Year Growth of 23% and 26% Respectively INGREZZA® (valbenazine) Full Year 2025 Net Product Sales Guidance of $2.5 - $2.6 Billion CRENESSITYTM (crinecerfont), a First-in-Class Treatment for Children and Adults with Classic Congenital Adrenal Hyperplasia, Approved and Launched in the United States Phase 3 Programs for Osavampator in Major Depressive Disorder and NBI-'568 in Schizophrenia Initiating in the First Half of 2025 SAN DIEGO, Feb. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the fourth quart
Conference Call and Webcast Scheduled for Thursday, February 6 SAN DIEGO, Jan. 30, 2025 /PRNewswire/ --Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that it has scheduled its fourth quarter and year-end 2024 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on February 6, 2025. The schedule for the press release and conference call / webcast is as follows: Q4 & Year-End 2024 Press Release: February 6, 2025 at 1:00 p.m. PT / 4:00 p.m. ETQ4 & Year-End 2024 Conference Call: February 6, 2025 at 1:30 p.m. PT / 4:30 p.m. E
SAN DIEGO, Jan. 28, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the initiation of a Phase 3 registrational study to evaluate the efficacy, safety and tolerability of osavampator (formerly NBI-1065845), an investigational drug under development as an adjunctive treatment to antidepressants for major depressive disorder (MDD). Positive topline data for the Phase 2 SAVITRI™ study of osavampator in adult subjects with MDD were announced in April 2024. "Osavampator has the potential to become a first-in-class treatment for MDD, a disorder that im
- Neurocrine Obtains Exclusive Worldwide Development and Commercialization Rights Excluding Japan and Converts to Royalty-Bearing License for Osavampator - Takeda Reacquires Rights to Osavampator in Japan SAN DIEGO, Jan. 27, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced it has amended its agreement with Takeda to develop and commercialize osavampator (NBI-1065845/TAK-653). Under the amended agreement, Neurocrine will obtain exclusive rights for all indications to develop and commercialize osavampator, a potential first-in-class AMPA positive allosteric modulator in development for patients with inadequate response to treatment of major depressive
SAN DIEGO, Jan. 23, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that Andrew Ratz, Ph.D., has joined the company as Senior Vice President of Drug Development, Delivery and Device. In this role, Dr. Ratz will lead the continued transformation of Neurocrine's Chemistry, Manufacturing and Controls organization to meet the needs of the company's growing research and development portfolio. Dr. Ratz joins Neurocrine after a 28-year career at Eli Lilly and Company, where he contributed to the development and successful registration of more than 25 p
SAN DIEGO, Jan. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced publication of a classic congenital adrenal hyperplasia (CAH)-focused supplement in The Journal of Clinical Endocrinology & Metabolism (JCEM), sponsored by the company. The supplement, titled "Challenges and Opportunities in the Management of Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency Throughout the Lifetime," contains eight review articles that provide a comprehensive look at the clinical, psychosocial, treatment-related and day-to-day challenges faced by individuals with classic CAH. JCEM is a leader in disseminating research that supports healthcare providers, p
Narrative Review Assesses Current Treatment Challenges and the Evolving Classic Congenital Adrenal Hyperplasia (CAH) Therapeutic LandscapeNon-Glucocorticoid (GC) Mechanisms for Treatment of CAH Could Enable Control of Excess ACTH and Androgens Without the Need for High-Dose GCs, Reducing Related Complications Over a LifetimeSAN DIEGO, Jan. 8, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced publication of a narrative review discussing the challenges of traditional treatment of classic congenital adrenal hyperplasia (CAH) with glucocorticoids (GCs) alone and the potential benefits of introducing novel non-GC mechanisms for treating the condition that may enable
SAN DIEGO, Jan. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) will present at the 43rd Annual J.P. Morgan Healthcare Conference at 8:15 a.m. Pacific Time on Monday January 13, 2025 in San Francisco. Kyle Gano, Chief Executive Officer, will present at the conference. The live presentation will be webcast and may be accessed on the Company's website under Investors at www.neurocrine.com. A replay of the presentation will be available on the website approximately one hour after the conclusion of the events and will be archived for approximately one month. Abo
CRENESSITY, a First-in-Class Treatment for Classic Congenital Adrenal Hyperplasia (CAH), is now commercially available in the U.S.CAH-trained pharmacists are available 24/7 to support patients with prescriptions exclusively through PANTHERx Rare, a specialty pharmacyNeurocrine Access Support is available to provide free, comprehensive access and support information to patients, caregivers and healthcare providersSAN DIEGO, Dec. 20, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced CRENESSITY™ (crinecerfont) is now commercially available in the United States. CRENESSITY was recently approved by the U.S. Food and Drug Administration as an adjunctive treatment to g
SC 13G - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)
SC 13G/A - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)
SC 13G/A - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)
SC 13G/A - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)
SC 13G/A - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)
SC 13G/A - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)
SC 13G/A - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)
Deutsche Bank initiated coverage of Neurocrine Biosciences with a rating of Hold and set a new price target of $138.00
Raymond James resumed coverage of Neurocrine Biosciences with a rating of Outperform and set a new price target of $155.00
Piper Sandler upgraded Neurocrine Biosciences from Neutral to Overweight and set a new price target of $159.00 from $131.00 previously
Wells Fargo upgraded Neurocrine Biosciences from Equal Weight to Overweight and set a new price target of $170.00 from $140.00 previously
Citigroup resumed coverage of Neurocrine Biosciences with a rating of Neutral and set a new price target of $127.00
Deutsche Bank initiated coverage of Neurocrine Biosciences with a rating of Buy and set a new price target of $136.00
Cantor Fitzgerald resumed coverage of Neurocrine Biosciences with a rating of Overweight and set a new price target of $140.00 from $135.00 previously
Mizuho reiterated coverage of Neurocrine Biosciences with a rating of Neutral and set a new price target of $113.00 from $112.00 previously
SVB Securities upgraded Neurocrine Biosciences from Market Perform to Outperform and set a new price target of $125.00 from $115.00 previously
BMO Capital Markets upgraded Neurocrine Biosciences from Underperform to Market Perform and set a new price target of $96.00 from $91.00 previously
Board of Directors appoints Kyle Gano, Ph.D., Chief Business Development and Strategy Officer, as CEO-elect, effective October 11, 2024 Kevin Gorman, Ph.D., to continue to serve on the Neurocrine Board of Directors SAN DIEGO, May 28, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX), today announced that Kevin Gorman, Ph.D., will retire as Chief Executive Officer of Neurocrine on October 11, 2024. Kyle Gano, Ph.D., currently Neurocrine's Chief Business Development and Strategy Officer, will succeed him in the CEO role. Dr. Gano will also join the Company's Board of Directors at that time, and Dr. Gorman will continue to serve on the Neurocrine Board.
SAN DIEGO, July 11, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that it appointed Christine A. Poon, a business leader with extensive experience in the pharmaceutical industry, to its Board of Directors. "Christine Poon brings a wealth of industry experience to Neurocrine's Board of Directors," said William H. Rastetter, Chairman of the Board of Neurocrine Biosciences. "Her strong track record in leadership positions at some of the most established global biopharmaceutical enterprises will serve Neurocrine well." Ms. Poon has demonstrated br
SAN DIEGO, Sept. 29, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that Dr. Ingrid Delaet will join the company's executive management team as Chief Regulatory Officer effective October 1, leading the regulatory affairs, quality assurance, medical writing, and program management teams. Dr. Delaet has served as Vice President of Regulatory Affairs at Neurocrine since January 2021. "Ingrid's deep experience in regulatory affairs will be invaluable to Neurocrine as we work to advance our pipeline in our quest to relieve suffering for people with
SAN DIEGO, Nov. 30, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that Jude Onyia, Ph.D., has joined the company's executive management team as Chief Scientific Officer. Dr. Onyia, a scientist with more than 25 years of experience in the pharmaceutical industry, will lead the drug discovery and non-clinical development teams responsible for bolstering and advancing the company's pipeline of therapeutic candidates. Dr. Onyia most recently was the Chief Scientific Officer at Capsida Biotherapeutics. Prior to that, he spent 25 years at Eli Lilly
SAN DIEGO, April 16, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the appointment of Johanna Mercier to its Board of Directors. Ms. Mercier is the Chief Commercial Officer of Gilead Sciences, with responsibility for the global commercialization of Gilead's medicines. "We are pleased to add Johanna Mercier to the Board of Directors at Neurocrine Biosciences," said William H. Rastetter, Chairman of the Board of Neurocrine Biosciences. "Johanna is an accomplished commercial leader and her extensive global experience within the biopharmaceutical
INGREZZA® (valbenazine) Fourth Quarter and Full Year 2024 Net Product Sales of $615 Million and $2.3 Billion, Representing Year-Over-Year Growth of 23% and 26% Respectively INGREZZA® (valbenazine) Full Year 2025 Net Product Sales Guidance of $2.5 - $2.6 Billion CRENESSITYTM (crinecerfont), a First-in-Class Treatment for Children and Adults with Classic Congenital Adrenal Hyperplasia, Approved and Launched in the United States Phase 3 Programs for Osavampator in Major Depressive Disorder and NBI-'568 in Schizophrenia Initiating in the First Half of 2025 SAN DIEGO, Feb. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the fourth quart
Conference Call and Webcast Scheduled for Thursday, February 6 SAN DIEGO, Jan. 30, 2025 /PRNewswire/ --Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that it has scheduled its fourth quarter and year-end 2024 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on February 6, 2025. The schedule for the press release and conference call / webcast is as follows: Q4 & Year-End 2024 Press Release: February 6, 2025 at 1:00 p.m. PT / 4:00 p.m. ETQ4 & Year-End 2024 Conference Call: February 6, 2025 at 1:30 p.m. PT / 4:30 p.m. E
INGREZZA® (valbenazine) Third Quarter Net Product Sales of $613 Million Representing 26% Year-Over-Year Growth INGREZZA® (valbenazine) 2024 Net Product Sales Guidance Raised to $2.30 - $2.32 Billion Board Authorizes $300 Million Share Repurchase Plan SAN DIEGO, Oct. 30, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the third quarter ended September 30, 2024 and provided an update on its 2024 financial guidance. "With continued INGREZZA growth across the tardive dyskinesia and Huntington's disease chorea indications,
Conference Call and Webcast Scheduled for Wednesday, October 30 SAN DIEGO, Oct. 9, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that it has scheduled its third quarter 2024 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) on October 30, 2024. The schedule for the press release and conference call / webcast is as follows: • Q3 2024 Press Release: October 30, 2024 at 4:00 a.m. PT / 7:00 a.m. ET • Q3 2024 Conference Call: October 30, 2024 at 5:00 a.m. PT / 8:00 a.m. ET • Domestic D
NBI-1117568 is an oral, muscarinic M4 selective receptor agonist discovered by Nxera advancing through clinical development under a multi-program collaboration with Neurocrine BiosciencesThe once-daily 20 mg dose efficacy, safety and tolerability Phase 2 results support advancement to Phase 3 in schizophrenia in early 2025The once-daily 20 mg dose met the primary endpoint, demonstrating a statistically significant 7.5-point improvement (p=0.011, 0.61 effect size) in the PANSS total score compared to placebo at week 6 with an 18.2-point PANSS total score improvement from baselineThe once-daily 20 mg dose met additional endpoints, demonstrating statistically significant improvements in Clinica
The Once-Daily 20 mg Dose Met the Primary Endpoint, Demonstrating a Statistically Significant 7.5-Point Improvement (p=0.011, 0.61 Effect Size) in the PANSS Total Score Compared to Placebo at Week 6 with an 18.2-Point PANSS Total Score Improvement from BaselineThe Once-Daily 20 mg Dose Met Additional Endpoints, Demonstrating Statistically Significant Improvements in Clinical Global Impression of Severity Scale and Marder Factor Score Positive Symptom Change and Negative Symptom ChangeNBI-'568 Was Generally Safe and Well Tolerated at All Doses StudiedThe Once-Daily 20 mg Dose Efficacy, Safety and Tolerability Phase 2 Results Support Advancement to Phase 3 in Schizophrenia in Early 2025Company
INGREZZA® (valbenazine) Second Quarter Net Product Sales of $580 Million Representing 32% Year-Over-Year Growth INGREZZA® (valbenazine) 2024 Net Product Sales Guidance Raised to $2.25 - $2.3 Billion Top-Line Phase 2 Data Readouts for NBI-'568 and Luvadaxistat Remain On Track in Q3 SAN DIEGO, Aug. 1, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the second quarter ended June 30, 2024 and provided an update on its 2024 financial guidance. "At Neurocrine, we are energized by the tremendous opportunity we see to help many
Conference Call and Webcast Scheduled for Thursday, August 1 SAN DIEGO, July 11, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that it has scheduled its second quarter 2024 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) on August 1, 2024. The schedule for the press release and conference call / webcast is as follows: • Q2 2024 Press Release: August 1, 2024 at 4:00 a.m. PT / 7:00 a.m. ET • Q2 2024 Conference Call: August 1, 2024 at 5:00 a.m. PT / 8:00 a.m. ET • Domestic Dial-In Numb
INGREZZA® (valbenazine) First Quarter Net Product Sales of $506 Million Representing 23% Year-Over-Year Growth INGREZZA® SPRINKLE (valbenazine) Capsules Approved by the U.S. FDA Crinecerfont New Drug Applications for the Treatment of Congenital Adrenal Hyperplasia Submitted to the U.S. FDA Positive Phase 2 Top-Line Data for NBI-1065845, a Potential First-In-Class AMPA Positive Allosteric Modulator, in Adults with Major Depressive Disorder SAN DIEGO, May 1, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the first quarter ended March 31, 2024 and provided an update on its 2024 financial guidance.
Conference Call and Webcast Scheduled for Wednesday, May 1 SAN DIEGO, April 10, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that it has scheduled its first quarter 2024 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) on May 1, 2024. The schedule for the press release and conference call / webcast is as follows: • Q1 2024 Press Release: May 1, 2024 at 4:00 a.m. PT / 7:00 a.m. ET • Q1 2024 Conference Call: May 1, 2024 at 5:00 a.m. PT / 8:00 a.m. ET • Domestic Dial-In Number: 800-343-4136
144 - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)
144 - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)
10-K - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)
8-K - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)
SCHEDULE 13G - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)
8-K - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)
8-K - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)
8-K - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)
10-Q - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)
8-K - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)